Growth hormone therapy with a new delivery system.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The Nordiject pen has been investigated both with respect to patient acceptance and bioavailability of the B-hGH (Norditropin) injected with the device.

The patients had no problems with the handling of the pen and approximately 2/3 of them experienced less injection pain with the pen compared to the syringe.

Who Took Part

By PubMed's age tags, the people studied were children and adults.

Twenty-seven children with growth retardation were included in a study.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Biological Availability, Drug Delivery Systems, Growth Disorders, Growth Hormone, Human Growth Hormone, Patient Satisfaction and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1992 (Indian journal of pediatrics), a journal based in India.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.